Retatrutide's combined GIP, GLP-1, and glucagon receptor activity produced substantial weight loss in trials, but long-term safety and cardiovascular outcomes remain essential.
Three pathways, one therapeutic strategy
Retatrutide is an investigational triple-hormone receptor agonist. GIP activity supports insulin secretion and glucose control; GLP-1 activity reduces appetite and slows gastric emptying; glucagon activity may increase energy expenditure and fat oxidation.
What the trial program suggests
- Phase 2 reported mean weight loss up to 24.2% at 48 weeks with the 12 mg dose.
- Topline phase 3 reporting cited 28.3% mean weight loss at 80 weeks with 12 mg.
- Glycemic, lipid, blood-pressure, and body-composition improvements were also observed.
Clinical caution
Gastrointestinal adverse events were the most common and were generally mild to moderate. Longer follow-up is needed to establish durability, rare harms, and cardiovascular outcomes.
References
- Jastreboff AM, et al. N Engl J Med. 2023;389:514-526.
- Medeasy Review, Issue 01, pp. 7-9.
Educational summary from Medeasy Review Issue 01. Verify recommendations against current guidelines, local approvals, product information, and the individual patient's circumstances.
